Clinicopathologic study of large cell anaplastic lymphoma (Ki-1-positive large cell lymphoma) among the Japanese.
The clinical, prognostic, phenotypic, and genotypic findings of 30 patients with large cell anaplastic lymphoma (Ki-1-positive large cell lymphoma) were analyzed. There were 13 male and 17 female patients (male-female ratio, 0.8) whose ages ranged from 3 to 81 years of age (mean, 28 years of age; 67% of the patients younger than 30 years of age). The 5-year survival rate was 52%; this was better than that of other types of high-grade peripheral T-cell lymphoma. Histologic examination showed distinctive morphologic features such as tumor cell pleomorphism, sinus infiltration, fibrosis, partial lymph node involvement, sparing of B-cell regions, and occasional plasma cell infiltrates. Eighty percent of the cases were of T-cell phenotype, and others expressed neither B-cell nor T-cell markers. The tumors were frequently positive for a histocompatibility antigen (HLA-DR), CD25 (the interleukin-2 receptor), and epithelial membrane antigen. Rearrangements of the T-cell receptor beta gene were observed in nine of 13 cases (69%). These findings indicated that many of the tumors had the phenotype and genotype of activated T-cells. This study also showed that large cell anaplastic lymphoma has a survival figure intermediate between Hodgkin's disease and low-grade peripheral T-cell lymphoma.
Nakamura
S
S
Department of Pathology and Clinical Laboratories, Aichi Cancer Center Hospital, Nagoya, Japan.
Takagi
N
N
Kojima
M
M
Motoori
T
T
Kitoh
K
K
Osada
H
H
Suzuki
H
H
Ogura
M
M
Kurita
S
S
Oyama
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000032:analysis; D001402:B-Lymphocytes / Q000473:pathology; D015139:Blotting, Southern; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003593:Cytoplasm / Q000648:ultrastructure; D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis; D006689:Hodgkin Disease / Q000401:mortality; D006801:Humans; D007124:Immunoenzyme Techniques; D007564:Japan; D016403:Lymphoma, Large B-Cell, Diffuse / Q000208:ethnology* / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015388:Organelles / Q000648:ultrastructure; D010641:Phenotype; D011379:Prognosis; D015996:Survival Rate; D013601:T-Lymphocytes / Q000473:pathology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D006684:HLA-DR Antigens